Bavarian Nordic announced preliminary unaudited 2025 financial results on February 12, 2026, highlighting strong demand for travel vaccines.278
Travel Health revenue showed significant growth, with the business increasing by 30%.2
The company provides guidance for 2026 indicating lower revenue and operating profit compared to 2025.45
Investor analysis suggests potential for upward adjustments to the 2026 expectations.5
This follows Q3 2025 interim results with 32% revenue increase to DKK 4,793 million and refined 2025 full-year guidance of ~DKK 6,000 million revenue.1
Sources:
1. https://www.biospace.com/press-releases/bavarian-nordic-announces-interim-results-for-the-first-nine-months-of-2025
2. https://www.vax-before-travel.com/2026/02/12/travel-vaccine-business-increases-30
4. https://medwatch.com/News/Pharma_Biotech/article19012011.ece
5. https://medwatch.com/News/Pharma_Biotech/article19021446.ece